Four details:
1. The study is implanting MagnetOs Putty on one side of the spine and autograft — the control material — on the other side.
2. Thirty patients will undergo a two-level instrumented posterolateral fusion.
3. The primary endpoint is the rate of posterolateral lumbar/thoracolumbar fusion, which is evaluated at 12 months.
4. MagnetOs Putty has a surface area that promotes bone growth throughout the graft for more predictable fusions, the company said in an April 13 news release.
Click here for more details on the study.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
